Why is Air Canada canceling flights this week?
How did Trump’s tariffs impact US producer prices?
What caused Applied Materials’ stock to plunge?
Why is the US government considering a stake in Intel?
How is GPT-5 influencing AI coding and enterprise use?
Why is Berkshire Hathaway reducing its Apple stake?
What’s driving the surge in Bitcoin prices today?
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
benzinga.com/news/health-care/25/08/47062562/merck-pfizer-backed-therapy-improves-outcomes-for-cisplatin-ineligible-bladder-cancer-patients
On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.
In this study, Keytruda (pembrolizumab) plus Padcev…
This story appeared on benzinga.com, 2025-08-12 14:46:59.